NCT02603809
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
See it on ClinicalTrials.gov ↗490 people
39.2%
60.8%
513 womenmiddle line = equal numbers796 men
- Phase
- PHASE2
- Paid for by
- Idorsia Pharmaceuticals Ltd.
- Finished
- 2017-04-07
- Health conditions
- Essential Hypertension
- Who could join
- Anyone
- Ages
- 18 Years – 75 Years
- Average age
- mean 54.7 years
- Age 65+
- Not reported
- Weight (BMI)
- mean 30.5 kilograms per square meter
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 62.8% · Black / African American 35.3% · Asian 0.9% · American Indian / Alaska Native 0.8% · Native Hawaiian / Pacific Islander 0.2% · More than one race 0% · Not reported 0%
Women left out
- No pregnant women
Women who were pregnant could not join.
“Women of childbearing potential must have a negative pregnancy test and use of reliable methods of contraception”
- Had to use birth control
Women who couldn't or didn't want to use birth control were turned away.
“Women of childbearing potential must have a negative pregnancy test and use of reliable methods of contraception”
- Weight limit (BMI)
Women with a higher (or lower) body weight were turned away.
“Body mass index \< 20 kg/m2 or \> 40 kg/m2”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Myocardial infarction, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft within 12 months prior to randomization”
- No mental health conditions
Women with depression, bipolar disorder or other mental health conditions were turned away.
“Treatment with any medication which may affect BP (e.g., treatment of psychiatric diseases, ophthalmic preparations)”
Study titles and rules are shown in their original English.